Stock 603998 HUNAN FANGSHENG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hunan Fangsheng Pharmaceutical Co., Ltd.

Equities

603998

CNE100001VG6

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
11.82 CNY +2.07% Intraday chart for Hunan Fangsheng Pharmaceutical Co., Ltd. +2.60% +7.85%
Apr. 19 Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 10 Fangsheng Pharma's Factories Pass GMP Inspection MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 2,920 3,521 4,819 5,196 -
Enterprise Value (EV) 1 2,920 3,521 4,819 5,196 5,196
P/E ratio 42.5 x 12.1 x 26.1 x 23.2 x 18.2 x
Yield - 4.37% 1.82% 0.85% 1.14%
Capitalization / Revenue - 1.96 x 2.96 x 2.47 x 2.07 x
EV / Revenue - 1.96 x 2.96 x 2.47 x 2.07 x
EV / EBITDA - 13.9 x 17.5 x 12.7 x 10.8 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - 2.54 x 3.31 x 3.26 x 2.94 x
Nbr of stocks (in thousands) 429,430 439,602 439,734 439,587 -
Reference price 2 6.800 8.010 10.96 11.82 11.82
Announcement Date 4/28/22 3/30/23 4/19/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 1,792 1,629 2,103 2,507
EBITDA 1 - 253.8 275.5 408.5 481.5
EBIT 1 - 165.7 196.4 263.5 332.5
Operating Margin - 9.25% 12.06% 12.53% 13.26%
Earnings before Tax (EBT) 1 - 326.6 203.3 260.5 329.5
Net income 1 70.04 285.9 186.8 224.5 284
Net margin - 15.95% 11.47% 10.68% 11.33%
EPS 2 0.1600 0.6600 0.4200 0.5100 0.6500
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 - 0.3500 0.2000 0.1000 0.1350
Announcement Date 4/28/22 3/30/23 4/19/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 22.1% 12.6% 14.1% 16.1%
ROA (Net income/ Total Assets) - 10.2% - 7.3% 8.35%
Assets 1 - 2,813 - 3,075 3,401
Book Value Per Share 2 - 3.160 3.320 3.630 4.020
Cash Flow per Share 2 - 0.7000 0.2000 0.8200 1.040
Capex 1 - 169 210 120 105
Capex / Sales - 9.45% 12.87% 5.68% 4.17%
Announcement Date 4/28/22 3/30/23 4/19/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hunan Fangsheng Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.82 CNY
Average target price
10.31 CNY
Spread / Average Target
-12.77%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
HUNAN FANGSHENG PHARMACEUTICAL CO., LTD. Stock Hunan Fangsheng Pharmaceutical Co., Ltd.
+7.85% 718M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.98% 43.67B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.67% 22.51B
SANDOZ GROUP AG Stock Sandoz Group AG
+14.56% 14.6B
CIPLA LIMITED Stock Cipla Limited
+14.32% 13.74B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+44.72% 11.91B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.37% 7.04B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+11.90% 5.42B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603998 Stock
  4. Financials Hunan Fangsheng Pharmaceutical Co., Ltd.